0
0

VALID Act of 2020

2/8/2022, 11:16 PM

Congressional Summary of HR 6102

Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020

This bill requires the Food and Drug Administration to regulate in vitro clinical tests (i.e., tests intended for the collection, preparation, analysis, or in vitro clinical examination of specimens from the human body in order to provide information about a disease, condition, or treatment for a disease or condition).

Current Status of Bill HR 6102

Bill HR 6102 is currently in the status of Bill Introduced since March 5, 2020. Bill HR 6102 was introduced during Congress 116 and was introduced to the House on March 5, 2020.  Bill HR 6102's most recent activity was Referred to the House Committee on Energy and Commerce. as of March 5, 2020

Bipartisan Support of Bill HR 6102

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
1
Democrat Cosponsors
0
Republican Cosponsors
1
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 6102

Primary Policy Focus

Health

Potential Impact Areas

- Administrative law and regulatory procedures
- Administrative remedies
- Advisory bodies
- Congressional oversight
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Emergency medical services and trauma care
- Federal preemption
- Food and Drug Administration (FDA)
- Government information and archives
- Health technology, devices, supplies
- Licensing and registrations
- Medical tests and diagnostic methods
- Performance measurement
- User charges and fees

Alternate Title(s) of Bill HR 6102

VALID Act of 2020
To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
VALID Act of 2020
Verifying Accurate Leading-edge IVCT Development Act of 2020

Comments